Clinical Trials Logo

Sunitinib clinical trials

View clinical trials related to Sunitinib.

Filter by:
  • None
  • Page 1

NCT ID: NCT01215578 Terminated - Clinical trials for Neuroendocrine Tumors

Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

NET
Start date: October 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to identify predictive molecular markers of response to continuous daily sunitinib at dose of 37.5 mg used in patients with poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors. Hypothesis: - To distinguish molecular markers based on their expression at the initial biopsy, their detection by proteomic analysis and demonstrating that tumor or vascular cells are straightaway sensitive to sunitinib (markers sensitivity). - The presence of these markers at the initial biopsy predict the sensitivity to sunitinib(Positive predictive value of markers)